|
|
|
|
|
12.11.25 - 14:06
|
Astria Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update (Business Wire)
|
|
|
-- BioCryst's Acquisition of Astria Expected to Close in the First Quarter of 2026 --
-- Phase 3 ALPHA-ORBIT Trial for Navenibart is Progressing as Planned with Topline Results Anticipated in Early 2027; First Patient Now Enrolled in the ORBIT-EXPANSE Long-Term Extension Trial --
-- Final Phase 1b/2 ALPHA-STAR Results in 29 HAE Patients Reinforces Navenibart's Robust HAE Attack Prevention and Favorable Safety Profile --
-- STAR-0310, an OX40 Antagonist, Demonstrated a Best-In-Class Profile with Initial Phase 1a Data Presented at the European Academy of Dermatology and Venereology Congress --BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today reported financial results for the third quarter ended September 30, 2025, and provided a corporate update.
“We believe that the proposed transaction with BioCryst provides the best opportunity to advance navenibart, enabling people ...
|
|
|
05.11.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst common stock. The RSUs were granted as of November 3, 2025, as inducements material to each employee entering into employment with BioCryst. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23.10.25 - 13:03
|
BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present four abstracts at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) taking place in Orlando, Fla., from November 6-10, 2025. The data will include results from a second interim analysis of the APeX-P trial evaluating long-term prophylaxis with an oral granule formulation of once-daily ORLADEYO® (berotralstat) in pediatric patients with hereditary angioedema (HAE) aged 2 to...
|
|
|
|
|
|
|
15.10.25 - 10:00
|
Astria Therapeutics: Übernahme beschert sharedealsPlus +200% nach Tipp (Sharedeals)
|
|
|
Die nächste Übernahme, die nächste Party für Mitglieder von sharedealsPlus: Mit der Aktie von Astria Therapeutics feiert die Community einen Verdreifacher in nur sechs Monaten. Mit einem Paukenschlag stärkt BioCryst Pharmaceuticals seine Position im lukrativen Markt für seltene Erkrankungen: Das US-Biotechunternehmen kündigte die Übernahme von Astria Therapeutics an. Die Transaktion, bestehend aus Bargeld und Aktien, […]
The post Astria Therapeutics: Übernahme beschert sharedealsPlus +200% nach Tipp first appeared on sharedeals.de....
|
|
|
|
|
|
|
|
|
|
|
|
|
03.10.25 - 13:03
|
BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire EN)
|
|
|
RESEARCH TRIANGLE PARK, N.C., Oct. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted eight newly-hired employees stock options to purchase an aggregate of 115,000 shares, and restricted stock units (RSUs) covering an aggregate of 91,450 shares, of BioCryst common stock. The options and RSUs were granted as of October 1, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4)....
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
